Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02462122 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

A Phase 3 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 3
Development phase
215
Enrollment target

NCT02462122: Completed Phase 3 study, sponsored by Bausch Health Americas.

NCT02462122 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 215 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02462122, a Phase 3 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 3
Development phase
215 participants
Enrollment target

Study Summary

Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis

Primary Outcome

Treatment success was defined as at least a 2-grade improvement from Baseline in IGA score and an IGA score equating to "Clear" or "Almost Clear". IGA was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Interventions

  • DRUG IDP-118 Lotion
  • DRUG IDP-118 Vehicle Lotion

Trial Details

FieldValue
Enrollment Target 215 participants
Start Date 2015-08-19
Est. Completion 2016-11-14
Phase Phase 3
Bausch Health Americas

168 total trials

What the finished NCT02462122 record still lists

NCT02462122 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 2 interventions - of which IDP-118 Lotion is the first listed.

NCT02462122 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02462122 about?

NCT02462122 is a clinical study titled "Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis". Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis

What is the current status of trial NCT02462122?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 215 participants. The study started on 2015-08-19. Estimated completion is 2016-11-14.

What interventions are being tested in trial NCT02462122?

The interventions under investigation include: IDP-118 Lotion (DRUG), IDP-118 Vehicle Lotion (DRUG).

Who is sponsoring clinical trial NCT02462122?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02462122's enrollment target sits among peer trials

215 1334th of 2000 higher than 666 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05134012 · 215 participants · Phase 3

    RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

  • NCT05169970 · 215 participants · Phase 2

    A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

  • NCT05197270 · 215 participants · Phase 1

    4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

  • NCT05230199 · 215 participants · NA

    Sensory Optimization of the Hospital Environment

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02462122, the US trial registry maintained by the National Library of Medicine. NCT02462122 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.